TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc. has announced a proposed sale of 1,000 common shares by Brett Sandercock, an officer of the company, under Rule 144 of the Securities Act of 1933. This transaction, set to occur on December 1, 2025, follows previous sales of 3,000 shares each in September, October, and November 2025, reflecting a strategic move by the officer to liquidate a portion of his holdings. The sale is valued at approximately $244,160 and will be conducted through Fidelity Brokerage Services LLC on the NYSE, indicating a continued trend of share sales by company insiders, which could have implications for investor perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, specializing in the development and manufacturing of equipment related to sleep disorders, particularly sleep apnea. The company focuses on providing innovative solutions for respiratory care, improving the quality of life for patients with chronic respiratory conditions.
Average Trading Volume: 1,249,949
Technical Sentiment Signal: Buy
Current Market Cap: A$55.4B
See more data about RMD stock on TipRanks’ Stock Analysis page.